A woman with multiple sclerosis (MS) has become the first person in the UK to receive a new "game-changer" 10-minute ...

Ocrelizumab also helps to prevent Multiple Sclerosis (MS) relapses. The new method has been used at Swansea Bay University ...

Subcutaneous administration of ocrelizumab was noninferior to intravenous infusion in the phase 3 OCARINA II trial.

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

The FDA has approved Roche’s subcutaneous injection for relapsing multiple sclerosis (RMS) and primary progressive multiple ...

Biologic drugs are typically given as infusions ... treats patients who have relapsing and progressive forms of MS. The injection is administered every six months, just like Ocrevus.

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

But the medication ocrelizumab, external, which helps to prevent relapses and slow the progression of MS, has now been approved as an injection and the first dose was given at Morriston Hospital.

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...